Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: +86-155-10908448
Mobile: +86-15510908448
Tel: +86-155-10908448
Fax: +86-15510908448
URL: http://www.kindpharma.biz
Province/state: Tianjin
City: Tianjin
Street: No.22 Quanwang Road, Wuqing Development Zone, Tianjin, China
MaxCard:
CAS NO.51333-22-3
Factory direct sales reliable high quality Budesonide 51333-22-3 with cheap price, accept customization.
Budesonide is a highly potent non-halogenated glucocorticoid specifically designed for local treatment of lung diseases, aiming for a high ratio between local and systemic effects.
Structurally, it is a glucocorticoid steroid with a highly oxygenated pregna-1,4-diene structure. Budesonide finds primary use in treating asthma, non-infectious rhinitis, and preventing nasal polyposis. It serves as an anti-inflammatory drug, a bronchodilator agent, and a drug allergen. This corticosteroid undergoes rapid transformation by cytochrome P450 3A4 in the liver, producing mainly inactive metabolites, thereby minimizing systemic steroid effects by about 90%. This characteristic makes budesonide particularly attractive for treating inflammatory bowel diseases, as it combines effectiveness with a low risk of systemic side effects. Studies have shown its efficacy in autoimmune hepatitis (AIH), demonstrating that it can achieve remission without the side effects associated with traditional steroids like prednisone.
Long-Term Effects of Budesonide or Nedocromil in Children with Asthma
The Childhood Asthma Management Program Research Group*
N Engl J Med 2000; 343:1054-1063
We randomly assigned 1041 children from 5 through 12 years of age with mild-to-moderate asthma to receive 200 μg of budesonide (311 children), 8 mg of nedocromil (312 children), or placebo (418 children) twice daily. We treated the participants for four to six years. All children used albuterol for asthma symptoms.
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease
Ole Østergaard Thomsen, M.D., D.M.Sci., Antoine Cortot, M.D., Ph.D., Derek Jewell, M.A., D.Phil., John P. Wright, M.D., Ph.D., Trevor Winter, M.D., Fernando Tavarela Veloso, M.D., Ph.D., Morten Vatn, M.D., Ph.D., Tore Persson, Ph.D., and Eva Pettersson, Ph.D. for the International Budesonide–Mesalamine Study Group*
N Engl J Med 1998; 339:370-374
Budesonide capsules contain granules that allow the slow release of the drug, mainly in the ileum and the ascending colon. In patients with active Crohn's disease affecting the ileum, the ascending colon, or both, a controlled-ileal-release formulation of budesonide was more effective in inducing remission than a slow-release formulation of mesalamine.